

Selected Innovative Medicines in Development as of July 16, 2025



Oncology (1 of 3)

AKEEGA (niraparib/abiraterone)
M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

IMBRUVICA (ibrutinib)
Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

RYBREVANT (amivantamab)
Subcutaneous (PALOMA-3)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma TNI (CARTITUDE-5)

ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)

RYBREVANT (amivantamab)
Colorectal Cancer 2L (ORIGAMI-3)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

TAR-200 (RIS/gemcitabine plus cetrelimab)
High Risk Non Muscle Invasive Bladder Cancer BGC Experienced (SunRISe-5)

DARZALEX (daratumumab)
Smoldering Multiple Myeloma (AQUILA)

IMBRUVICA (ibrutinib)
Frontline Mantle Cell Lymphoma (Triangle)

TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer (SunRISe-1)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

JNJ-1900 (NBTXR3)
Head and Neck Cancer

TALVEY + TECVAYLI
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

TALVEY (talquetamab)
TIE NDMM in combination with DR (MajesTEC-7)

TAR-210 (RIS/erdafitinib)
Intravesical Delivery System for Localized Bladder Cancer (MoonRISe-1)

DARZALEX (daratumumab)
Frontline multiple myeloma transplant ineligible (CEPHEUS)

RYBREVANT (amivantamab)
Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

Bleximenib
Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

ERLEADA (apalutamide)
Localized Prostate Cancer (ATLAS)

RYBREVANT (amivantamab)
Colorectal Cancer (ORIGAMI-2)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

TECVAYLI (teclistamab)
Multiple Myeloma 1-3PLs (MajesTEC-3)

Oncology (2 of 3)

TECVAYLI (teclistamab) TE NDMM maintenance (MajesTEC-4)	TECVAYLI (teclistamab) TIE NDMM in combination with DR (MajesTEC-7)	TECVAYLI (teclistamab) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)
bleximenib Relapsed Refractory Acute Myeloid Leukemia (ALE1001)	JNJ-0683 (ARX788) Breast Cancer	JNJ-1900 (NBTXR3) Lung Cancer
TALVEY + TECVAYLI Relapsed Refractory Multiple Myeloma (RedirecTT-1)	JNJ-0387 Solid Tumors	JNJ-0631 (ARX305) Renal Cancer
JNJ-1493 Hematological Malignancies	JNJ-2638 Gastrointestinal Cancer	JNJ-2761 Multiple Myeloma
JNJ-3413 Lymphoma	JNJ-4496 Hematological Malignancies	JNJ-4680 Lung Cancer
JNJ-4681 Hematological Malignancies	JNJ-4916 Lung Cancer	JNJ-5322 Multiple Myeloma
JNJ-6420 Prostate Cancer	JNJ-8177 (ARX517) Prostate Cancer	JNJ-8343 Prostate Cancer
JNJ-8377 Lymphoma	JNJ-8543 Hematological Malignancies	JNJ-9401 Prostate Cancer

Oncology (3 of 3)

JNJ-9530
Hematological Malignancies

JNJ-9892
Hematological Malignancies

JNJ-9968
Hematological Malignancies

Immunology (1 of 2)

SIMPONI (golimumab)
Pediatric Ulcerative Colitis (PURSUIT 2)

TREMFYA (guselkumab)
Crohn's Disease (GALAXI)

TREMFYA (guselkumab)
Crohn's Disease Subcutaneous Induction (GRAVITI)

icotrokinra
Psoriasis (ICONIC)

nipocalimab
Sjogren's Disease

STELARA (ustekinumab)
Pediatric Ulcerative Colitis (UNIFI JR)

TREMFYA (guselkumab)
Pediatric Ulcerative Colitis (QUASAR JR)

JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis

STELARA (ustekinumab)
Pediatric Crohn's Disease (UNITI JR)

TREMFYA (guselkumab)
Pediatric Psoriasis (PROTOSTAR)

TREMFYA (guselkumab)
Ulcerative Colitis Subcutaneous Induction (ASTRO)

icotrokinra
Psoriatic Arthritis

nipocalimab
Hemolytic Disease of the Fetus and Newborn (AZALEA)

TREMFYA (guselkumab)
Psoriatic Arthritis Structural Damage (APEX)

icotrokinra
Ulcerative Colitis

JNJ-4804 Co-antibody Therapy
Crohn's Disease

STELARA (ustekinumab)
Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)
Ulcerative Colitis (QUASAR)

TREMFYA (guselkumab)
Pediatric Juvenile Psoriatic Arthritis

nipocalimab
Warm Autoimmune Hemolytic Anemia (ENERGY)

nipocalimab
Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

TREMFYA (guselkumab)
Pediatric Crohn's Disease (MACARONI-23)

JNJ-4804 Co-antibody Therapy
Ulcerative Colitis

JNJ-5939
Atopic Dermatitis

Immunology (2 of 2)

nipocalimab Combination Therapy
Rheumatoid Arthritis

JNJ-5108
Immunological Diseases

nipocalimab
Systemic Lupus Erythematosus

JNJ-7528
Atopic Dermatitis

nipocalimab
Idiopathic Inflammatory Myopathy

Neuroscience

CAPLYTA (lumateperone) Adjunctive Treatment for Major Depressive Disorder
SPRAVATO (esketamine) Treatment Resistant Depression monotherapy (TRD4005)
nipocalimab Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)
ITI-1284 Generalized Anxiety Disorder
JNJ-1887 sCD59 Geographic Atrophy
posdinemab Alzheimer's Disease (AUTONOMY)

IMAAVY (nipocalimab) Generalized Myasthenia Gravis (Vivacity MG3)
CAPLYTA (lumateperone) Bipolar Mania
RPGR Gene Therapy Retinitis Pigmentosa (LUMEOS)
ITI-1284 Alzheimer's Disease-Related Psychosis
JNJ-2056 (tau active immunotherapy) * Alzheimer's Disease (RETAIN)
SPRAVATO (esketamine) Major Depressive Disorder with Suicidal Ideation Pediatrics

IMAAVY (nipocalimab) Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)
CAPLYTA (lumateperone) Pediatric Psychiatric Indications
seltorexant Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms (OARS)
ITI-1284 Alzheimer's Disease-Related Agitation
JNJ-5120 Major Depressive Disorder

Select Other Areas

CABENUVA

HIV Adolescents

milvexian (Factor Xla)

Acute Coronary Syndrome

UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

milvexian (Factor Xla)

Atrial Fibrillation

SIRTURO

Tuberculosis Long Acting

milvexian (Factor Xla)

Secondary Stroke Prevention

SIRTURO

Leprosy

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of July 16, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CART-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited

